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ABSTRACT
Objective To evaluate if prostate specific antigen test
attainsvaliditystandardsrequiredforscreeninginviewof
recent prostate cancer screening trial results.
Design Case-control study nested in longitudinal cohort.
Setting Västerbotten Intervention Project cohort, Umeå,
Sweden.
Participants 540 cases and 1034 controls matched for
age and date of blood draw.
Main outcome measure Validity of prostate specific
antigen for prediction of subsequent prostate cancer
diagnosis by record linkage to cancer registry.
Results Blood samples were drawn on average 7.1 (SD
3.7) years before diagnosis. The area under the curve for
prostate specific antigen was 0.84 (95% confidence
interval 0.82 to 0.86). At prostate specific antigen cut-off
values of 3, 4, and 5 ng/ml, sensitivity estimates were
59%,44%,and33%,andspecificityestimateswere87%,
92%, and 95%. The positive likelihood ratio commonly
considered to “rule in disease” is 10; in this study the
positive likelihood ratios were 4.5, 5.5, and 6.4 for
prostate specific antigen cut-off values of 3, 4, and 5 ng/
ml. The negative likelihoodratiocommonlyconsidered to
“rule out disease” is 0.1; in this study the negative
likelihood ratios were 0.47, 0.61, and 0.70 for prostate
specific antigen cut-off values of 3, 4, and 5 ng/ml. For a
cut-off of 1.0 ng/ml, the negative likelihood ratio was
0.08.
Conclusions No single cut-off value for prostate specific
antigen concentration attained likelihood ratios formally
required for a screening test. Prostate specific antigen
concentrations below 1.0 ng/ml virtually ruled out a
prostate cancer diagnosis during the follow-up.
Additional biomarkers for early detection of prostate
cancer are needed before population based screening for
prostate cancer should be introduced.
INTRODUCTION
Serumconcentrationsofprostatespecificantigenhave
been widely used for early detection of prostate
cancer,
1-3 and prostate specific antigen has been
described as the best circulating tumour marker in
oncology.
4-6 Recently, the European Randomized
Study of Screening for Prostate Cancer (ERSPC)
reporteda20%decreaseintherateofdeathfrompros-
tate cancer in the screening arm; however, consider-
able overdiagnosis and overtreatment occurred in the
screeningarm, as1068men had to bescreenedand 48
men had to have curative treatment in order to save
one man’s life.
7 These data highlight the need for a
rigorousexaminationofthevalidityofprostatespecific
antigen as a screening test for prostate cancer.
Cross sectional studies have shown that approxi-
mately 10% of middle aged men have prostate specific
antigen concentrations above 4 ng/ml and approxi-
mately a quarter of these men have prostate cancer on
biopsy.
89 Studies of this design can provide accurate
dataonthepositivepredictivevalueofprostatespecific
antigen for diagnosis of prostate cancer, as men with
high prostate specific antigen concentrations have
biopsy for verification of the diagnosis. These studies
can also provide relatively accurate estimates of speci-
ficitygiventhatprostatecancerisrelativelyrareamong
men with low prostate specific antigen
concentrations.
10-12 However, in cross sectional stu-
dies, cancer status is not verified in men with prostate
specificantigenconcentrationsbelowthethresholdfor
biopsy, so such studies cannot provide accurate esti-
mates of sensitivity. Estimates of sensitivity are neces-
sary for calculation of likelihood ratios,
13 which
describe the likelihood that a given test result would
be expected in a person with a disease compared with
the likelihood that the same result would be expected
in a person without the disease. A positive likelihood
ratioabove10foradiagnostictestisconsideredtobea
strongevidenceto“rulein”disease,whereasanegative
likelihood ratio below 0.1 is considered sufficient evi-
dence to “rule out” disease.
14 Importantly, likelihood
ratios are not affected by the prevalence of the disease
13;
likelihoodratiosare,therefore,powerfultoolsforevaluat-
ing biomarkers.
Sensitivity, specificity, and likelihood ratios can be
calculated only when case status is known for all parti-
cipants in a study. Case status is known both in studies
in which all men have biopsy regardless of prostate
specific antigen concentration and in longitudinal
cohort studies in which prostate specific antigen is
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cancer registry and in matched controls.
15-21
The aim of this study was to evaluate prostate speci-
fic antigen as a screening test by calculating the sensi-
tivity, specificity, and likelihood ratios of prostate
specific antigen concentrations in predicting subse-
quent diagnosis of prostate cancer in a case-control
study nested in a longitudinal cohort.
METHODS
Study population
The Västerbotten Intervention Project is an ongoing
long term population based cohort study in which all
residents in Västerbotten County are invited to a
health examination at the age of 40, 50, and 60 years.
22 The health examination includes measurement of
height, weight, and blood pressure, as well as a blood
draw. Blood is fractioned into plasma, buffy coat, and
erythrocyte aliquots and cryopreserved at −80°C. By
December2005,theVästerbottenInterventionProject
comprised37031menwhohadhadahealthexamina-
tion and blood draw. The participation rate was 57%,
and comparison of participants with non-participants
in the study has shown relatively small differences in
social characteristics and overall health status.
23
In January 2006 we linked the Västerbotten Inter-
vention Project cohort to the regional cancer registry
andidentified654incidentcasesofprostatecancer.Of
these cases, 540 (83%) men had a prospectively col-
lectedbloodsampleavailableforbiochemicalanalysis
for this study. Clinical characteristics of tumours,
including local stage, lymph node stage, metastasis at
bone scan, tumour differentiation, and serum prostate
specific antigen concentration at the time of diagnosis
came from the Northern Sweden part of the National
ProstateCancerRegister.
24Were-evaluatedcorebiop-
sies in accordance with Gleason and measured the
length of the core biopsies and cancer tissue in the
cores. We defined high risk prostate cancer as local
tumour stage T3 or T4, Gleason score 8 or higher,
World Health Organization grade III (WHO grading
was assessed on fine needle aspirate done in 64 men),
orpresenceoflymphnodemetastasis,bonemetastasis,
or serum prostate specific antigen concentrations
above 20 ng/ml. No formal screening programme for
prostatecancerhasbeenorisinoperationinthesource
population.
As the Västerbotten Intervention Project partici-
pants are recruited at even decades, 98% of our study
group consisted of three age clusters: one cluster of
men aged 39-40 (n=16) at the time of blood draw, one
cluster of men aged 49-50 (n=129), and one cluster of
men aged 59-60 (n=386). To keep the large cluster
intact in subgroup analyses, we divided the partici-
pants into one group younger than 59 years at recruit-
ment (n=148 cases) and one group aged 59 or older at
recruitment(n=392cases).Foreachcase,werandomly
selected two controls (1.9 on average; 1034 in total)
who were alive and free of cancer at the time of diag-
nosis for the index case, within sets matched to the
index case for age (six months younger or older than
the index case) and date of recruitment (within two
months before or after blood draw of the index case).
All participants gave written informed consent at the
time of recruitment.
Biochemical analysis
Baseline plasma prostate specific antigen concentra-
tions were determined with Wallac Delfia assays
(AutoDelfia, Wallac Oy, Turku, Finland) at the
Department of Clinical Chemistry, Helsinki Univer-
sity Central Hospital, Helsinki, Finland. Cases and
their matched controls were analysed in the same
batch, and laboratory personnel were blinded to case-
control status. At prostate specific antigen concentra-
tions between 0.2 and 100 ng/ml, the intra-assay and
inter-assay coefficients of variation were in the range
2-4%. Serum prostate specific antigen concentrations
in blood drawn shortly before the diagnostic biopsies
hadbeendeterminedwitheitherHybritechTandem-R
(Hybritech Inc, San Diego, CA) or the IMx prostate
specific antigen assay (Abbot Laboratories, Abbot
Park,IL),andvalueshadbeenrecordedintheNational
Prostate Cancer Register. The coefficient of correla-
tion between the two assays was 0.990 (IMx value=
(1.22×Tandem value)−2.80).
25
Statistical methods
We used conditional logistic regression to calculate
odds ratios for diagnosis of prostate cancer. We calcu-
lated specificity and sensitivity for a series of prostate
specific antigen cut-off values and estimated the area
under the curve in receiver operating characteristics
curves for the full study group and for subgroups stra-
tified according to low/high risk cancer, age at blood
draw (<59 years and ≥59 years), and time from blood
draw to diagnosis. We calculated the positive likeli-
hood ratio as sensitivity/(1−specificity) and the nega-
tive likelihood ratio as (1−sensitivity)/specificity. We
used the positive and negative likelihood ratios to esti-
mate the probability of diagnosis of prostate cancer
PSA concentration (ng/ml)
0.1 1 10  100 
Controls
Cases
Fig 1 | Distribution of plasma prostate specific antigen (PSA)
concentrations in cases and controls. Curves indicate
frequency functions of calculated normal distribution of
logarithm of PSA concentrations according to mean and
standard deviation in cases and controls. Histogram shows
observed distribution of logarithm of PSA concentrations in
cases and controls
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specific antigen concentration (post-test probability),
assumingabaselineprobabilityofdiagnosisofprostate
cancer during follow-up of 10%.
1326 We used SAS 9.1
for statistical analyses.
RESULTS
The median plasma concentration of prostate specific
antigen was 3.6 (interquartile range 2.2-6.2) ng/ml
among cases and 1.1 (0.7-2.0) ng/ml in controls. The
mean time from the date of blood draw to the date of
diagnosis was 7.1 (SD 3.7) years. The median age at
baselinewas57.7(5.4)yearsinbothcasesandcontrols.
Age at date of blood draw among controls was posi-
tivelycorrelatedwithprostatespecificantigenconcen-
trations (r=0.23, P<0.001). Figure 1 shows the
distribution of prostate specific antigen concentrations
in cases and controls.
Table 1 shows the characteristics of the tumours. At
the time of diagnosis, 445 (86%) cases had a clinical
local stage T1 or T2 tumour. Prostate specific antigen
concentrations at diagnosis were higher than10 ng/ml
in285(56%)men,187(35%)caseshadatumourdiffer-
entiation Gleason score of 7 or higher or WHO grade
III, and 41 (12%) cases had bone metastasis. Investiga-
tions werestartedafterprostatespecificantigen testing
at a health check-up in 118 (23%) men and for symp-
tomsorothercausesin391(77%)men.Highriskpros-
tate cancer was present in 185 (34%) cases.
Compared with a reference group of men with pros-
tate specific antigen concentrations below 1 ng/ml,
men with concentrations between 1 and 2 ng/ml had
an odds ratio of diagnosis of prostate cancer during
follow-up of 9.1 (95% confidence interval 5.0 to 16.5).
For men with prostate specific antigen concentrations
between2and3ng/ml,theoddsratiowas23.3(12.3to
43.9); for those with concentrations between 3 and 4
ng/ml, the odds ratio was 43.9 (22.1 to 87.3); for
those with concentrations between 4 and 10 ng/ml,
the odds ratio was 68.1 (35.2 to 130.6); and for men
with prostate specific antigen concentrations above
10 ng/ml, the odds ratio was 239.5 (89.3 to 642.3).
Validity of prostate specific antigen in predicting
subsequent prostate cancer diagnosis during follow-up
In the full group, the area under the curve for prostate
specificantigenwas0.84(95%confidenceinterval0.82
to 0.86). It was higher for cases with a short lag time
thanforthosewithalonglagtime,higheramongcases
aged under 59 at the time of recruitment than in those
over 59, and higher for high risk tumours than for low
risk tumours (table 2).
Table 3 shows estimates of sensitivity, specificity,
likelihoodratio,andpost-testprobability.Thesensitiv-
ity was 44% and the specificity 92% when we used a
prostate specific antigen cut-off of 4.0 ng/ml in the
full study group. When we decreased the cut-off to
3.0ng/ml,thesensitivityincreasedto59%andthespe-
cificity decreased to 87%. With a prostate specific anti-
gen cut-off of 4.0 ng/ml, the positive and negative
likelihood ratios were 5.45 and 0.61; with a prostate
specific antigen cut-off of 3.0 ng/ml the positive and
negative likelihood ratios were 4.51 and 0.47. Among
483 men with prostate specific antigen concentrations
below 1.0 ng/ml, 19 (3.9%) were diagnosed as having
prostate cancer. The negative likelihood ratio for a
Table 1 |Characteristics of cases and tumours
Characteristic Cases (n=540)
Continuous variables— —median (5th-95th centile)
Age at diagnosis (years) 64.6 (54.6-71.2)
Time between blood draw and diagnosis (years) 6.9 (1.0-13.7)
Prostate specific antigen at diagnosis (ng/ml) 11 (4-145)
Prostate specific antigen at blood draw (ng/ml) 3.6 (1.1-20.6)
Fraction of malignant tissue in biopsy (%) 7.0 (0-60)
Discrete variables— —No (%)
Mode of diagnosis:
Health check-up 118 (23.2)
Symptoms, other reasons 391 (76.8)
Missing 31
Stage:
T1a, b 24 (4.7)
T1c 244 (47.4)
T2 177 (34.4)
T3 64 (12.4)
T4 6 (1.2)
TX 25
Lymph node metastasis:
N0 164 (92.1)
N1 14 (7.9)
NX 362
Bone metastasis:
M0 315 (88.5)
M1 41 (11.5)
MX 184
Gleason score:
2-6 295 (63.0)
7 130 (27.8)
8-10 43 (9.2)
Missing 72
WHO grade where Gleason score missing:
I2 5 ( 3 9 . 1 )
II 25 (39.1)
III 14 (21.9)
Missing 8
Prostate specific antigen at diagnosis (ng/ml):
0-4 24 (4.7)
4-10 204 (39.8)
10-20 147 (28.7)
20-50 75 (14.6)
50-100 29 (5.7)
≥100 34 (6.6)
Missing 27
High/low risk cancer*:
Low risk 355 (65.7)
High risk 185 (34.3)
*High risk defined as clinical local tumour stage T3 or T4, lymph node
metastasis (N1), bone metastasis (M1), Gleason score ≥8, WHO grade III,
or serum levels of prostate specific antigen at diagnosis >20 ng/ml; low
risk defined as absence of all of these factors.
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Six (1.2%) cases with prostate specific antigen concen-
trations below 1.0 ng/ml were diagnosed as having
high risk prostate cancer, and for those men the time
between blood draw and diagnosis was between five
and 13 years.
Using the positive and negative likelihood ratio esti-
mates, assuming a baseline risk of 10% of diagnosis of
prostate cancer during the follow-up, we estimated the
probability of diagnosis of prostate cancer (post-test P)
foramanwithaprostatespecificantigenconcentration
above 4.0 ng/ml to be 0.38 and that for a man with a
concentration below 4.0 ng/ml to be 0.06. The corre-
sponding post-test probability for prostate cancer with
aprostatespecificantigenconcentrationabove1.0ng/
mlwas0.16,andthatforaconcentrationbelow1.0ng/
mlwas0.01.Figure2showsaFagan’snomogramillus-
trating post-test probabilities.
27
DISCUSSION
In this longitudinal study, the distribution of prostate
specific antigen concentrations in cases and controls
largelyoverlapped.Nocut-offvalueforprostatespeci-
fic antigen concentrations resulted in positive and
negative likelihood ratios requiredfor a screening test.
Prostate specific antigen based screening
The European Randomized Study of Screening for
ProstateCancer(ERSPC)recentlyshowedthatscreen-
ing and early intervention can reduce the rate of death
from prostate cancer but at the cost of considerable
overdiagnosis and overtreatment.
7 The Prostate,
Lung, Colorectal, and Ovarian (PLCO) Cancer
Screening Trial found no significant difference in the
rate of death from prostate cancer between the screen-
ing group and the control group.
28 However, the
PLCO result probably reflects contamination among
controls of whom a large proportion had been tested
for prostate specific antigen.
Best available biomarker for cancer
In comparison with other putative biomarkers, pros-
tatespecificantigenconfersextremelyhighoddsratios
even for modestly raised concentrations,
2930 and our
estimates of sensitivity, specificity, and area under the
curve were largely similar to results obtained in pre-
vious studies with the same longitudinal study design,
despite relatively large differences in age at recruit-
ment, lag time, and characteristics of the tumours.
16-21
These results confirm that circulating prostate specific
antigen is a robust marker with a relatively high valid-
ity in predicting a future diagnosis of prostate cancer.
However, when screening a population with a rela-
tively low prevalence of prostate cancer, extremely
high validity must be achieved. In particular, the spe-
cificity should exceed 95% to avoid unnecessary,
potentially harmful and costly follow-up procedures
in a large number of healthy people.
3132 In our study,
a prostate specific antigen cut-off value of 5.0 ng/ml
was needed to achieve a specificity of 95%, a cut-off
resultinginasensitivityofmerely33%.Thedifficulties
in finding a prostate specific antigen cut-off value
resulting in a sufficiently high specificity concurrently
with a reasonably high sensitivity (that is, above 50%)
are graphically illustrated in figure 1 by the large over-
lap in the distribution of prostate specific antigen con-
centrations in cases and controls.
Table 2 |Area under curve for categories of cases
Study group No (cases) Area under curve (95% CI)
Full study group 540 0.84 (0.82 to 0.86)
High/low risk cancer*:
Low risk 355 0.83 (0.80 to 0.85)
High risk 185 0.88 (0.85 to 0.91)
Age at blood draw†:
<59 years 148 0.87 (0.84 to 0.91)
≥59 years 392 0.84 (0.82 to 0.87)
Lag time‡:
<2 years 33 0.95 (0.92 to 0.98)
>10 years 109 0.76 (0.72 to 0.80)
<4 years 138 0.92 (0.90 to 0.94)
≥4 years 402 0.82 (0.80 to 0.84)
*High risk defined as clinical local tumour stage T3 or T4, lymph node
metastasis (N1), bone metastasis (M1), Gleason score ≥8, WHO grade III,
or serum levels of prostate specific antigen at diagnosis >20 ng/ml; low
risk defined as absence of all of these factors.
†Same as age at recruitment.
‡Time from blood draw to diagnosis.
Post-test
probability
Likelihood
ratio
Pre-test
probability
PSA=20
PSA=10
PSA=4
PSA=3
PSA=1
PSA=0.5
0.999
1000
500
200
100
50
20
10
5
2
1
0.5
0.2
0.1
0.05
0.02
0.01
0.005
0.002
0.001
0.998
0.997
0.995
0.993
0.99
0.98
0.97
0.95
0.93
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1 0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.07
0.05
0.03
0.02
0.01
0.007
0.005
0.003
0.002
0.001 0.999
0.998
0.997
0.995
0.993
0.99
0.98
0.97
0.95
0.93
0.07
0.05
0.03
0.02
0.01
0.007
0.005
0.003
0.002
0.001
Fig 2 | Fagan’s nomogram for calculation of post-test
probabilities. Blue (solid) arrows indicate post-test probability
of diagnosis during follow-up for men with prostate specific
antigen (PSA) concentrations above given cut-offs. Red
(broken) arrows indicate post-test probability of diagnosis
during follow-up for men with PSA concentrations below given
cut-offs
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Estimates of likelihood ratios are powerful tools in
evaluating the clinical usefulness of a screening test,
as likelihood ratios are not affected by the prevalence
of a disease.
13 However, to the best of our knowledge,
likelihood ratios have not been used to evaluate pros-
tatespecificantigenasascreeningtestforprostatecan-
cer.Theusefulnessofascreeningtestisdeterminedby
how well it predicts disease, and this can be evaluated
by using likelihood ratios while adapting for various
existing risk factors for disease. Hence, a risk estimate
can be estimated on the basis of a combination of risk
factors, rather than using a single cut-off value.
13 A
positive likelihood ratio above 10 for a diagnostic test
isconsideredtobestrongevidenceto“rulein”disease,
whereasanegativelikelihoodratiobelow0.1isconsid-
ered sufficient evidence to “rule out” disease.
14 In our
data, no single cut-off value for prostate specific anti-
gen resulted in positive and negative likelihood ratios
close to these values. However, a cut-off of 1.0 ng/ml
resultedina negativelikelihoodratioof0.08,and only
six (1.2%) men diagnosed as having high risk cancer
hadpre-diagnosticprostatespecificantigenconcentra-
tions below 1.0 ng/ml, suggesting that this cut-off may
be usefulin identifying menwith verylow risk of pros-
tate cancer. This result is in accordance with data from
ascreeningstudyinGothenburg,Sweden,inwhichno
man with a prostate specific antigen concentration
below1.0ng/mlwasdiagnosedashavingprostatecan-
cer during three years of follow-up.
26
Strengths and limitations
Baselinecharacteristicsofastudypopulationinfluence
estimates of validity. In particular, characteristics of
tumours affect estimates of sensitivity, and one advan-
tageofourstudywasthatthecasemixmirroredthatof
the source population, a property strengthening the
external validity of our study.
24 The standardised inci-
dencerateratioforprostatecancerintheVästerbotten
Intervention Project cohort was 1.05 (95% confidence
interval 0.96 to 1.16) compared with the source popu-
lation up to 2002. Another advantage of our study was
the relatively low frequency of testing for prostate spe-
cific antigen. Notably, our dataset represented a “best
case scenario,” in that the likelihood ratios in popula-
tions with a higher uptake of testing for prostate speci-
ficantigenandconsequentlyalargerproportionoflow
risk tumours will be substantially less advantageous
than we observed.
15
Characteristicsof controlsaffect estimatesof specifi-
city, and the median concentration and distribution of
prostatespecificantigenconcentrationsinourcontrols
were very similar to those in the European Rando-
mized Study of Screening for Prostate Cancer.
8 The
specificity estimates obtained in our study were also
similar to those obtained in other investigations with
similar, and different, study designs.
151920 Hence, the
results of this study can be extrapolated to other white
Europeanpopulationsinwhichnowidespreadscreen-
ingwithprostatespecificantigentestsisongoing.How-
ever, the lack of long follow-up is a limitation of our
study.
Conclusions
Althoughprostatespecificantigenhasarelativelyhigh
validity for prediction of subsequent prostate cancer,
this longitudinal study shows that no cut-off value for
Table 3 |Validity of prostate specific antigen (PSA) for prediction of subsequent prostate cancer diagnosis
PSA cut-off Sensitivity*
Positive
likelihood ratio†
Positive
post-test P‡ Specificity§
Negative
likelihood ratio¶
Negative
post-test P**
0.5 0.99 1.15 0.11 0.13 0.04 0.005
1 0.96 1.73 0.16 0.44 0.08 0.01
2 0.78 3.15 0.26 0.75 0.30 0.03
3 0.59 4.51 0.33 0.87 0.47 0.05
4 0.44 5.45 0.38 0.92 0.61 0.06
5 0.33 6.35 0.41 0.95 0.70 0.07
10 0.13 12.34 0.58 0.99 0.88 0.09
20 0.05 28.11 0.76 1.00 0.95 0.10
*Proportion of cases above PSA cut-off.
†Calculated as sensitivity/(1−specificity).
‡Probability of prostate cancer diagnosis during follow-up given PSA concentrations above cut-off.
§Proportion of controls below PSA cut-off.
¶Calculated as (1−sensitivity)/specificity.
**Probability of prostate cancer diagnosis during follow-up given PSA concentrations below cut-off.
WHAT IS ALREADY KNOWN ON THIS TOPIC
The performance of prostate specific antigen testing for early detection of prostate cancer is
good overall, as shown in both longitudinal and cross sectional studies
The European Randomized Study of Screening for Prostate Cancer (ERSPC) found a 20%
decrease in the rate of death from prostate cancer in the screening arm
However, overdiagnosis and overtreatment are a concern when using serum concentrations
of prostate specific antigen to screen for prostate cancer
WHAT THIS STUDY ADDS
No cut-off value for prostate specific antigen attained the likelihood ratios formally required
for a screening test
However, concentrations below 1.0 ng/ml virtually ruled out a subsequent diagnosis of
prostate cancer
These data, in combination with data from the recent screening trials, indicate that further
biomarkers are needed before population based screening for prostate cancer should be
introduced
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formally required for a screening test. However, pros-
tate specific antigen concentrations below 1.0 ng/ml
virtuallyruledoutadiagnosisofprostatecancerduring
follow-up,andhigherprostatespecificantigenconcen-
trationsexpressedacontinuumofprostatecancerrisk.
Takentogether,ourstudyandtherecentfindingsfrom
screening trials strongly indicate that in addition to
serum concentrations of prostate specific antigen,
further biomarkers are needed before population
based screening for prostate cancer can be recom-
mended.
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